Number of patients (%) | ||
---|---|---|
Group 1 (tetracosactide + valproate) n = 79 | Group 2 (dexamethasone + valproate) n = 18 | |
First 5 days of therapy | 40 (50.6%) | 7 (38.7%) |
Days 6–10 | 24 (34%) | 4 (22.2%) |
Days 11–30 | 9 (11.4%) | 2 (11.1%) |
IS ongoing | ||
6 (7.6%) (p = 0.0017) | 5 (28%) (p = 0.0017) | |
Without epileptiform discharges | 59 (74.7%) (p = 0.4) | 7 (38.9%) (p = 0.04) |
Multiregional epileptiform discharges | 1 (1.3%) | 6 (33.3%) |
Focal epileptiform discharges | 14 (17.7)% | 3 (16.7%) |
Hypsarrhythmia | 5 (6.%) | 2 (11.1%) |
Number of patients % | ||
---|---|---|
Group 1 (tetracosactide + valproate) n = 79 | Group 2 (dexamethasone + valproate) n = 18 | |
Hypoxic Ischemic Neonatal Encephalopathy | 51 (64.6%) | 13 (72.2%) |
Malformations of cerebral cortical development | 11 (13.9%) | 2 (11.1%) |
Metabolic disorders | 5 (6.3%) | 0 |
Chromosomal disorders | 2 (2.5%) | 0 |
Neuroinfections | 2 (2.5%) | 0 |
Cerebral hemorrhage | 1 (1.3) | 1 (5.5%) |
Cryptogenic IS | 7 (8.9%) | 2 (11.1%) |
Flexor IS | 48 (60.7%) | 12 (66.6%) |
Extensor IS | 12 (15.1%) | 3 (16.6%) |
Asymmetrical IS | 4 (5.1%) | 1 (5.5%) |
Combination of IS | 15 (18.9%) | 2 (11.1%) |
Clusters daily | ||
Up to 5 | 61 (77.2%) | 15 (83.3%) |
Up to 10 | 13 (16.5%) | 1 (5.5%) |
< 10 | 5 (6.3%) | 2 (11.1%) |
Up to 5 | 1 (1.2%) | 0 |
Up to 10 | 46 (58.2%) | 11 (61%) |
Dozens | 32 (40.5%) | 7 (39%) |
classical | 21 (26.6%) | 3 (16.6%) |
synchronized | 17 (21.5%) | 5 (28%) |
asymmetric | 5 (6.3%) | 0 |
with a consistent focus | 13 (16.4%) | 3 (16.6%) |
high amplitude asynchronous | 4 (5.1%) | 1 (5.5%) |
suppression-burst pattern | 16 (24.1%) | 6 (33.3%) |
Number of patients (%) | ||
---|---|---|
Group 1 (tetracosactide + valproate) n = 79 | Group 2 (dexamethasone + valproate) n = 18 | |
Upper respiratory infections | 21 (26.6%) | 4 (22.2%) |
Mucous membrane candidiasis | 16 (20.2%) | 1 (5.5%) |
Hypopotassemia | 12 (15.1%) | 2 (11.1%) |
Hypocalcemia | 3 (3.8%) | 1 (5.5%) |
Thrombocytopenia | 5 (6.3%) | 0 |
Hyponatremia | 0 | 1 (5.5%) |
No. of patients | ||
---|---|---|
Group 1 (tetracosactide + valproate) | Group 2 (dexamethasone + valproate) | |
79 | 18 | |
5.8 | 7.3 | |
53 | 13 | |
26 | 5 | |
2.04 | 2.6 |